The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly.
Affiliation
Department of Endocrinology, Christie Hospital, Manchester, UK.Issue Date
2004
Metadata
Show full item recordAbstract
Serum insulin-like growth factor I (IGF-I) is an important marker of disease activity in patients with acromegaly, and epidemiological data indicate control of circulating IGF-I in patients with acromegaly restores life expectancy to normal. Improvements in the quality of, and access to, IGF-I assays has encouraged monitoring of acromegaly with IGF-I, although circulating growth hormone (GH) and IGF-I values provide different information, so ideally both should be monitored. However, the introduction of the GH receptor antagonist pegvisomant poses new challenges. Pegvisomant binds with high affinity to GH receptors, thereby blocking the action of GH at the tissue level and rendering the hormone biologically inactive. This leaves IGF-I as the principal marker of disease activity. It is conceptually possible to induce a state of functional GH deficiency (GHD) with pegvisomant with IGF-I values within the normal range. With the goal of minimizing the risk of over-treatment and GHD, we have provided preliminary guidance on the target range for IGF-I in patients receiving pegvisomant based on the gender- and decade-based percentile ranges for IGF-I of adult patients with untreated GHD enrolled in the Pfizer International Metabolic Database (KIMS).Citation
The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly. 2004, 62 Suppl 1:83-8 Horm. Res.Journal
Hormone ResearchDOI
10.1159/000080764PubMed ID
15761238Type
ArticleLanguage
enISSN
0301-0163ae974a485f413a2113503eed53cd6c53
10.1159/000080764
Scopus Count
Collections
Related articles
- Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
- Authors: Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A
- Issue date: 2002 Apr
- Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
- Authors: Drake WM, Loureiro RA, Parkinson C, Monson JP, Besser GM, Trainer PJ
- Issue date: 2005 Jan
- The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
- Authors: Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ
- Issue date: 2003 Aug
- Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
- Authors: Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ
- Issue date: 2012 Apr
- Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
- Authors: Drake WM, Parkinson C, Besser GM, Trainer PJ
- Issue date: 2001 Nov